**Supplementary material**

**Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study**

**Running title: Antipsychotic and cardiometabolic drug discontinuation**

**Marco Solmi,1,2 Jari Tiihonen,3,4 Markku Lähteenvuo,3 Antti Tanskanen,3,5 Christoph U. Correll,6,7,8 Heidi Taipale3,5,9**

*1 Neurosciences Department, University of Padua, Italy*

*2 Padua Neurosciences Center, University of Padua, Italy*

*3 Niuvanniemi Hospital, Niuvankuja 65, 70240 Kuopio, Finland*

*4 Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, &
Stockholm Health Care Services, Region Stockholm, Norra Stationsgatan 69, 11364 Stockholm,
Sweden*

5 *Department of Clinical Neuroscience, Karolinska Institutet, Tomtebodavägen 18A, 171 77
Stockholm, Sweden*

*6 Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Charité University Medicine Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.*

*7 Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY 11004 USA.*

*8 Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra Blvd, Hempstead, NY 11549 USA.*

*9 School of Pharmacy, University of Eastern Finland, Yliopistonranta 1, 70210 Kuopio, Finland*

**Corresponding author:**

Marco Solmi, MD, PhD

Address: Neuroscience Department, University of Padua, Padua, Italy – Via Giustiniani, 5 - Padua - Italy

Tel: +39-0498213831 Fax: +39-0498213836 E-mail: marco.solmi83@gmail.com

**Supplementary Table 1. Sensitivity analyses adjusted for psychiatric and non psychiatric visits.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Statin discontinuation | Antidiabetic discontinuation | Antihypertensive discontinuation | Betablocker discontinuation |
|  | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) |
| Any antipsychotic use vs. non-use | <.0001 | 0.66 (0.57-0.77) | <.0001 | 0.63 (0.53-0.75) | <.0001 | 0.67 (0.59-0.77) | 0.0021 | 0.87 (0.79-0.95) |
|  |  |  |  |  |  |  |  |  |
| Oral antipsychotic | <.0001 | 0.68 (0.58-0.79) | <.0001 | 0.66 (0.54-0.79) | <.0001 | 0.68 (0.59-0.78) | 0.103 | 0.92 (0.84-1.02) |
| Long-acting injectable | 0,0031 | 0.71 (0.56-0.89) | 0.0042 | 0.69 (0.53-0.89) | 0.0346 | 0.81 (0.67-0.99) | 0.0437 | 0.85 (0.73-0.99) |
| Polytherapy | <.0001 | 0.58 (0.48-0.69) | <.0001 | 0.56 (0.46-0.68) | <.0001 | 0.59 (0.51-0.69) | <.0001 | 0.75 (0.68-0.84) |